Literature DB >> 29846201

CORR® Tumor Board: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.

Megan E Anderson1, Jim S Wu, Sara O Vargas.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29846201      PMCID： PMC6437562          DOI： 10.1097/CORR.0000000000000349

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN： 0009-921X            Impact factor:   4.176


× No keyword cloud information.
  11 in total

1.  The challenges posed by cancer heterogeneity.

Authors:  Sangeeta Bhatia; John V Frangioni; Robert M Hoffman; A John Iafrate; Kornelia Polyak
Journal:  Nat Biotechnol       Date:  2012-07-10       Impact factor: 54.908

2.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.

Authors:  Matija Snuderl; Ladan Fazlollahi; Long P Le; Mai Nitta; Boryana H Zhelyazkova; Christian J Davidson; Sara Akhavanfard; Daniel P Cahill; Kenneth D Aldape; Rebecca A Betensky; David N Louis; A John Iafrate
Journal:  Cancer Cell       Date:  2011-12-01       Impact factor: 31.743

Review 3.  An Overview of the Changing Landscape of Treatment for Advanced Melanoma.

Authors:  Chung-Shien Lee; Christan M Thomas; Kimberly E Ng
Journal:  Pharmacotherapy       Date:  2017-02-17       Impact factor: 4.705

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Magnetic resonance imaging of osteosarcoma using a bis(alendronate)-based bone-targeted contrast agent.

Authors:  Pingju Ge; Fugeng Sheng; Yiguang Jin; Li Tong; Lina Du; Lei Zhang; Ning Tian; Gongjie Li
Journal:  Biomed Pharmacother       Date:  2016-09-25       Impact factor: 6.529

6.  Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines.

Authors:  Christopher D Collier; Emily C Wirtz; Gabrielle J Knafler; William Z Morris; Patrick J Getty; Edward M Greenfield
Journal:  Clin Orthop Relat Res       Date:  2018-07       Impact factor: 4.176

Review 7.  Intratumoral Heterogeneity of the Epigenome.

Authors:  Tali Mazor; Aleksandr Pankov; Jun S Song; Joseph F Costello
Journal:  Cancer Cell       Date:  2016-04-11       Impact factor: 31.743

8.  CXCR4-targeted near-infrared imaging allows detection of orthotopic and metastatic human osteosarcoma in a mouse model.

Authors:  Guofeng Guan; Yao Lu; Xiaodong Zhu; Lijuan Liu; Jie Chen; Qiong Ma; Yinglong Zhang; Yanhua Wen; Lianjia Yang; Tao Liu; Wei Wang; Henry Ran; Xiuchun Qiu; Shi Ke; Yong Zhou
Journal:  Sci Rep       Date:  2015-10-16       Impact factor: 4.379

Review 9.  Osteosarcoma: Accelerating Progress Makes for a Hopeful Future.

Authors:  Amanda J Saraf; Joelle M Fenger; Ryan D Roberts
Journal:  Front Oncol       Date:  2018-01-26       Impact factor: 6.244

Review 10.  Addressing intra-tumoral heterogeneity and therapy resistance.

Authors:  Brad Rybinski; Kyuson Yun
Journal:  Oncotarget       Date:  2016-11-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.